In light of our study and metformin as an FDA-approved drug, we are well-positioned to initiate a clinical trial to examine Mgll mRNA levels in AD patients' peripheral blood as a screening methodology to identify patients to receive effective metformin treatment. The gene discussed is MGLL; the disease is Alzheimer disease.